Navigate Fool.com
Will BMY beat
the market?
Community Rating: 4 Stars: Favorite

49.46 0.35 (0.71%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $49.04
Previous Close $49.11
Daily Range $48.95 - $49.68
52-Week Range $39.18 - $57.49
Market Cap $81.6B
P/E Ratio 32.12
Dividend (Yield) $1.44 (2.9%)
Ex-Dividend Date
Dividend Pay Date
Volume 6,670,783
Average Daily Volume 8,857,382
Current FY EPS $1.76

How do you think BMY
will perform against the market?

Top BMY Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

If This Biotech Drops Much Further I'm Going to Buy It!

This biotech behemoth dipped by more than 20% recently despite a growth rate that could easily equal 25% over the next five years. Needless to say, if it drops any further I'm going to buy it!

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

Gilead Sciences' oral hepatitis C drug Sovaldi has taken the market by storm, but Merck's looking to fight back in the race to capture this lucrative niche.

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides

Is the plummeting valuation justified?

2 Reasons Why Merck & Co. Is Crushing the Dow

Merck is up double digits this year and outperforming the major indexes. Why?

Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?

This Texas-based biotech reported positive proof-of-concept results earlier this week and could be set to upend a number of big pharmaceutical companies if its experimental drug continues to deliver.

How Much Has Merck Shaken Up the Hepatitis C Race?

Recent data presentations at the EASL conference highlight the emerging competition in hepatitis C.

This Forgotten Pharma Could Be a Hit for Your Portfolio

Roche combines a very deep oncology pipeline with some of the best growth and margins in Pharma

Noteworthy ETF Inflows: XLV, JNJ, AMGN, BMY

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Merck plays catch-up while Bristol-Myers looks global.

Amgen's Conundrum

What will Amgen do with T-VEC and will it be able to compete with Bristol-Myers Squibb's Yervoy, which is already on the market, and Merck's (NYSE: MRK) experimental anti-PD-1 antibody MK-3475.

See More BMY News...





Bristol-Myers Squibb Co. (BMY) Description

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments. Website: http://www.bms.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks